Iovance Q2 operating loss narrows to $51.91 million; revenue rises 66% year over year to $99.31 million - IOVA News | RalliesIovance Q2 operating loss narrows to $51.91 million; revenue rises 66% year over year to $99.31 million
I
IOVA• Guidance review and regulatory update
- Management is reviewing 2026 revenue guidance of USD 350 million to USD 370 million, with an update planned in 3Q.
- FDA granted Fast Track for lifileucel in soft tissue sarcomas.
Losses narrow and gross margin improves
- Operating loss narrowed to USD 51.91 million from USD 113.77 million a year earlier; net loss improved to USD 47.32 million from USD 111.66 million.
- Gross margin rose to 56%, reflecting higher Amtagvi volume, cost optimization, and maturing internal manufacturing efficiencies.
Q2 revenue rises on continued Amtagvi demand
- Iovance posted 2Q26 revenue of USD 99.31 million, up 66% year over year, driven by continued U.S. Amtagvi demand.
- U.S. Amtagvi revenue reached about USD 91 million; global Proleukin revenue was about USD 9 million, expected to grow through 2026.
•
